Takeda Pharmaceutical is a Japanese company that has been defending as many as 9,000 lawsuits or claims for individuals who were taking the medication Actos, which is a Type 2 diabetes drug. Takeda’s United States’ headquarters is located in Deerfield, Ill.
The filed complaints include 4,000 in Cook County, Ill., another 4,000 filed in Louisiana and about 800 filed in Florida. There are still other cases filed in federal court in the Western District of Louisiana; these are part of the Multidistrict Litigation (MDL). In one of those cases, tried to a jury in 2014, the verdict against Takeda and Eli Lilly was for $9 billion, which set a record. In that case Takeda was found to have destroyed evidence about Actos and its link to bladder cancer. It was also revealed that Takeda’s former employees and some top executives in the U.S. and Japan deleted files that if considered would have had negative impact. That verdict amount was later reduced by the presiding judge and is on the appeal filed by Takeda. That case as consolidated is titled In re Actos (Pioglitazone) Products Liability Litigation, 11- md-02299, U.S. District Court, Western District of Louisiana (Lafayette).
According to reports, the diabetes drug Actos produced $16 billion in sales since it went on the market for public use in 1999. In June 2011, the United States Food and Drug Administration (USDA) issued a written warning about the possible risk of bladder cancer for those patients who were taking Actos for a year or longer. In August 2011, the FDA issued a new warning about Actos stating that people taking Actos “may be an increased risk for developing bladder cancer.”